NEWARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, May 13, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2021 and to provide a business update.

Conference Call Details


To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13718350. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company’s website at

http://ir.cymabay.com/events

.

About CymaBay


CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA. CymaBay is currently conducting a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, phase 3 study to evaluate the safety and efficacy of seladelpar (RESPONSE) in patients with PBC. For more information about RESPONSE, please visit:

www.pbcstudies.com

.

For additional information about CymaBay visit

www.cymabay.com

.

Public Relations Contact


:

Glenn Silver

Lazar-FINN Partners

(973) 818-8198

[email protected]

Investor Relations Contact:

Hans Vitzthum

LifeSci Advisors, LLC

(617) 430-7578


[email protected]